Minimal Access, Metabolic & Bariatric Surgery (MAMBS) Department, Max Superspeciality Hospital, 1 & 2, Press Enclave Marg, Saket, New Delhi, 110017, India.
Obes Surg. 2021 Mar;31(3):1265-1270. doi: 10.1007/s11695-020-05129-4. Epub 2020 Nov 16.
Roux-en-Y gastric bypass (RYGB) has emerged as the most effective treatment in reversing insulin resistance in patients with type 2 diabetes mellitus (T2DM). A number of models and statistical tools have been proposed to predict patients likely to experience diabetes remission post-RYGB. The purpose of our study was to evaluate the preoperative accuracy of DiaRem score in predicting T2DM remission at 1 year of follow-up in a retrospective analysis of diabetic morbidly obese patients who underwent RYGB.
One hundred and forty-three patients underwent RYGB between January 2018 and December 2018. We conducted a retrospective analysis in 55 patients (38.46%) with T2DM with 1 year of follow-up. DiaRem score was calculated, and patients were stratified in five groups.
At a 1-year follow-up, we found a higher proportion of patients with T2DM remission in the lower score group compared to a lower proportion of patients with remission in the higher score group. We derived a DiaRem cut-off score of 6.5 that had high sensitivity and specificity to predict T2DM remission preoperatively. We found a significant decrease in BMI and HbA1C values post-operatively at 1 year following RYGB.
DiaRem score is an easy to determine score based on basic clinical parameters that could identify patients with T2DM who would achieve maximal benefit in terms of remission after bariatric surgery. The development of a suitable scoring tool would be clinically useful as it would enable clinicians to better triage patients for RYGB.
Roux-en-Y 胃旁路术(RYGB)已成为逆转 2 型糖尿病(T2DM)患者胰岛素抵抗的最有效治疗方法。已经提出了许多模型和统计工具来预测 RYGB 后可能经历糖尿病缓解的患者。我们研究的目的是在对接受 RYGB 的肥胖型糖尿病患者进行的回顾性分析中,评估 DiaRem 评分在预测 RYGB 后 1 年 T2DM 缓解方面的术前准确性。
143 例患者于 2018 年 1 月至 12 月期间接受 RYGB。我们对 55 例(38.46%)有 1 年随访的 T2DM 患者进行了回顾性分析。计算了 DiaRem 评分,并将患者分为五组。
在 1 年随访时,我们发现低评分组中 T2DM 缓解的患者比例较高,而高评分组中缓解的患者比例较低。我们得出 DiaRem 截断值为 6.5,该值具有术前预测 T2DM 缓解的高敏感性和特异性。我们发现 RYGB 后 1 年 BMI 和 HbA1C 值显著下降。
DiaRem 评分是一种基于基本临床参数的易于确定的评分,可识别出在减重手术后能获得最大缓解益处的 T2DM 患者。开发合适的评分工具在临床上很有用,因为它可以使临床医生更好地为 RYGB 患者进行分诊。